Literature DB >> 2440749

The thymic microenvironment. Characterization of in vitro differentiation of the IT26R21 rat thymic epithelial cell line.

D F Lobach, T Itoh, K H Singer, B F Haynes.   

Abstract

We have previously postulated an in vivo pathway of thymic epithelial (TE) cell maturation in pre- and postnatal thymus, whereby endocrine medullary TE cells terminally differentiate to form Hassall's bodies. Epithelial-cell differentiation has been well documented in vitro using epidermal keratinocytes. Therefore, to characterize TE-cell differentiation in vitro, we observed clones of the rat TE cell line, IT26R21, after 4 and 14 days in culture. We found alterations in cell morphology, the cessation of cell proliferation, and the acquisition of a differentiation antigen defined by monoclonal antibody TE-19 (a marker of terminally differentiated epithelial cells). At light and electron microscopy, we detected progressive TE-cell stratification and squamous-cell formation between 4 and 14 days of culture. Autoradiography on day 14 showed that squamous TE cells in stratified layers did not incorporate tritiated thymidine, while surrounding smaller cells adhering to the substratum continued to synthesize DNA. At indirect immunofluorescence, only 3% of cells reacted with monoclonal antibody TE-19 at day 4, while on day 14, 22% of the TE cells were TE-19 positive (P less than 0.02). Antibody-TE-19 reactivity was limited to stratified, squamous TE cells. Additionally, we isolated a clone of the IT26R21 cell line that did not undergo these changes characteristic of TE cell differentiation. We conclude that IT26R21 TE cells are capable of undergoing programs of both terminal differentiation and cell renewal in vitro.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440749     DOI: 10.1111/j.1432-0436.1987.tb00050.x

Source DB:  PubMed          Journal:  Differentiation        ISSN: 0301-4681            Impact factor:   3.880


  9 in total

Review 1.  Ontogeny of the human thymus during fetal development.

Authors:  D F Lobach; B F Haynes
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

2.  Establishment of functional epithelial cell lines from a rat thymoma and a rat thymus.

Authors:  A Masuda; K Ohtsuka; M Matsuyama
Journal:  In Vitro Cell Dev Biol       Date:  1990-07

3.  Thymic nurse cells in culture: morphological and antigenic characterization.

Authors:  D Toussaint-Demylle; J M Scheiff; S Haumont
Journal:  Cell Tissue Res       Date:  1993-05       Impact factor: 5.249

4.  Demonstration of phenotypic abnormalities of thymic epithelium in thymoma including two cases with abundant Langerhans cells.

Authors:  V B Kraus; E A Harden; B Wittels; J O Moore; B F Haynes
Journal:  Am J Pathol       Date:  1988-09       Impact factor: 4.307

Review 5.  The human thymus. A chimeric organ comprised of central and peripheral lymphoid components.

Authors:  B F Haynes; L P Hale
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 6.  The human thymus. A chimeric organ comprised of central and peripheral lymphoid components.

Authors:  B F Haynes; L P Hale
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

7.  Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus.

Authors:  L E French; A P Sappino; J Tschopp; J A Schifferli
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

8.  TGF-β type II receptor expression in thymic epithelial cells inhibits the development of Hassall's corpuscles in mice.

Authors:  Chikako Odaka; Mathias Hauri-Hohl; Kazuya Takizawa; Yomiko Nishikawa; Masashi Yano; Mitsuru Matsumoto; Richard Boyd; Georg A Holländer
Journal:  Int Immunol       Date:  2013-08-08       Impact factor: 4.823

9.  Rearrangements of desmosomal and cytoskeletal proteins during the transition from epithelial to fibroblastoid organization in cultured rat bladder carcinoma cells.

Authors:  B Boyer; G C Tucker; A M Vallés; W W Franke; J P Thiery
Journal:  J Cell Biol       Date:  1989-10       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.